Quantcast
Last updated on April 16, 2014 at 5:23 EDT

Latest PTC Therapeutics Stories

2013-11-14 08:33:24

-- Conference call to be held today at 8:00 a.m. ET -- SOUTH PLAINFIELD, N.J., Nov. 14, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT), a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes, today announced financial and corporate results for the quarter ended September 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) "2013 has thus far...

2013-11-07 08:33:19

SOUTH PLAINFIELD, N.J., Nov. 7, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that PTC management will host a webcast conference call to discuss financial results for the third quarter ended September 30, 2013 and provide a corporate update on Thursday, November 14, 2013 at 8:00 a.m. (ET) before the opening of the market. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) The call can be accessed by dialing 877-303-9216 (domestic) or (973)...

2013-11-05 16:27:34

SOUTH PLAINFIELD, N.J., Nov. 5, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the upcoming 2013 Credit Suisse Annual Health Care Conference on Tuesday, November 12 at 4:30 pm ET. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com. The...

2013-10-18 08:24:35

SOUTH PLAINFIELD, N.J., Oct. 18, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its first R&D Day on Friday, October 25, 2013 from 8:30 a.m. to 12:00 p.m. ET at the Four Seasons Hotel in New York City. Members of PTC's senior management and research teams will provide a corporate update and in-depth reviews of the company's scientific platforms and R&D programs. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO) A live...

2013-10-10 08:29:08

SOUTH PLAINFIELD, N.J., Oct. 10, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that the following two posters will be presented at the 27th Annual North American Cystic Fibrosis Conference in Salt Lake City, Utah, on October 17-19: -- The use of chronic inhaled antibiotics in the phase 3 clinical trial of ataluren in patients with nonsense mutation cystic fibrosis (poster number 207) -- Use of different pulmonary exacerbation definitions in...

2013-10-01 08:31:40

SOUTH PLAINFIELD, N.J., Oct. 1, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Mr. Martin Rexroad as Senior Vice President, Human Resources and Mr. R.A. Session II as Vice President, Corporate Development, both reporting to Ms. Claudia Hirawat, President of PTC Therapeutics, Inc. In addition, Dr. Jay Barth has been promoted to Senior Vice President, Clinical Development. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO) "It is...

2013-09-30 08:29:40

SOUTH PLAINFIELD, N.J., Sept. 30, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it was included on the list of quarterly initial public offering additions to the Russell 2000® Index to be effective at the close of the U.S. market on September 30, 2013. (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO) "We are very pleased to be included in the Russell 2000® Index," stated Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics,...

2013-09-27 16:23:58

SOUTH PLAINFIELD, N.J., Sept. 27, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that they will participate in two upcoming investor conferences. -- Management will participate in a roundtable discussion at the Lazard Capital Markets' GenomeRX: Genes as Drugs Workshop on Tuesday, October 1 at 4:00 pm ET in New York City. The roundtable is titled The Next Wave of RNAi/Targeting. -- Management will present a company overview at...

2013-09-25 16:26:33

SOUTH PLAINFIELD, N.J., Sept. 25, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that four posters will be presented at the 18(th) International World Muscle Society Congress (WMS) in Asilomar, California, on October 1-5. The following posters will be presented on October 3 from 14:30 - 16:00 during Dystrophinopathy pharmco and pharmaco-gene therapy Session. -- Phase 2b, dose-ranging study of ataluren (PTC124®) in nonsense mutation Duchenne muscular...

2013-09-18 08:29:10

SOUTH PLAINFIELD, N.J., Sept. 18, 2013 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced that two abstracts have been accepted for the 10(th) European Pediatric Neurology Society Congress (EPNS) in Brussels, Belgium, on September 25-28. -- Design of a confirmatory phase 3, multicenter, randomized, double-blind, placebo-controlled study of ataluren in patients with nonsense mutation Duchenne muscular dystrophy; -- Disease-related symptoms and...